Market News & Trends
Can-Fite Signs Multi-Million Dollar Distribution Agreement
Can-Fite BioPharma Ltd. recently announced it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment…
Confluence Pharmaceuticals Signs Co-Development & Marketing Agreement
Confluence Pharmaceuticals and AOP Orphan Pharmaceuticals AG recently announced they have signed a definitive agreement to co-develop and market Confluence’s lead asset, a product for the…
Alizé Pharma III Raises $1.94 Million for Osteoporosis Program
Alizé Pharma III SAS recently announced that it has raised $1.94 million in a first financing round. The funding round was supported by a syndicate…
Cloud Pharmaceuticals & University of Florida Collaborate on Rapid Design of Novel Cancer Inhibitors
Cloud Pharmaceuticals and the University of Florida Department of Medicine recently announced an academic collaboration that will help rapidly design and develop novel drugs to…
Identification of Foreign Particulate Matter Using Automated Raman & Automated SEM-EDS
By: Angela Flowers, Emily Landsperger, Rebekah Byrne, and Dave Exline, Gateway Analytical Foreign particulate matter in drug products is a common problem in the…
Ruthigen & Pulmatrix Enter Into Merger Agreement
Ruthigen, Inc. recently announced it have entered into a definitive merger agreement. Upon the closing of the transactions contemplated by the merger agreement, Pulmatrix will…
Key TxCell Patent to be Granted for its Lead Product
TxCell SA recently announced that a key patent is to be granted by the United States Patent and Trademark Office (USPTO). The issue notification has…
Immune Pharmaceuticals to Develop Novel Topical Nanoparticle Formulation
Immune Pharmaceuticals Inc. recently announced it has entered into a binding memorandum of understanding with Yissum, the Technology Transfer Company of the Hebrew University of…
Xcelience Receives DEA Approval to Develop & Manufacture DEA Schedule I Drug Products
Xcelience, a CDMO, located in Tampa, FL, is excited to announce that they have received approval from the Federal Drug Enforcement Agency to develop and…
Germany’s Pharmaceutical Market Value Will Crawl to $65 Billion
While Germany is the leading pharmaceutical market in Europe, valued at $58.6 billion in 2014, the sector will expand at a modest Compound Annual Growth…
The $700-Billion Connected Life Market That Will Drive Change & Growth
We are living a connected life in a connected world. Our smartphone is our gateway to the world, and very soon, we will be able…
From Volume to Value
By: Alan Shortall, Unilife Chairman & CEO As healthcare markets continue to shift to a model based on value-based outcomes, Bluetooth-enabled smart medical technologies…
New Mechanism for Engineering Genetic Traits Governed by Multiple Genes Paves Way for Various Advances
When it comes to gene expression, scientists have so far studied one single gene at a time. A new approach developed by Harvard geneticist George…
US Asthma Treatment Market Value to Hit $14 Billion
The US treatment market for asthma will rise in value from $11.7 billion in 2013 to an estimated $14 billion by 2020, representing a Compound…
AgeneBio Announces Phase II Clinical Trial Results
AgeneBio recently announced the publication of complete Phase II clinical trial results in NeuroImage: Clinical for its lead product candidate. The results show that AGB101…
Allergen Research Corporation Completes $80-Million Financing to Advance Drug Development Portfolio
Allergen Research Corporation (ARC) recently announced the completion of an $80- million Series B financing. Foresite Capital led the round, with participation from existing investor…
PhaseBio Raises $40 Million, Led By AstraZeneca
PhaseBio Pharmaceuticals, Inc., a leading company in the field of biopolymer-based drugs and focused on developing treatments for metabolic and specialty cardiopulmonary disorders, recently announced…
Charleston Laboratories & Daiichi Sankyo Announce Completion of Pharmacokinetics Study
Charleston Laboratories, Inc. and its co-development and co-commercialization partner, Daiichi Sankyo, Inc., recently announced the completion of a pharmacokinetics study on CL-108, Charleston Laboratories' lead…
Kura Oncology Announces License Agreement; Closes $60 Million
Kura Oncology, Inc. recently announced it has entered into an agreement with Janssen Pharmaceutica NV for an exclusive license to develop and commercialize tipifarnib in…
Impax Laboratories Completes Major Acquisitions
Impax Laboratories, Inc. recently announced it has completed its acquisition of Tower Holdings, Inc. (including operating subsidiaries CorePharma LLC and Amedra Pharmaceuticals LLC), and Lineage…
